Latest News and Press Releases

The 2025-2027 approval helps French innovators access Intravacc’s vaccine development, analytical development and cGMP manufacturing services.

Valable pour la période 2025–2027, cet agrément permet aux entreprises innovantes françaises de faire appel à l’expertise d’Intravacc dans le développement de vaccins, le développement analytique et...

Die Zulassung für den Zeitraum 2025–2027 ermöglicht französischen Innovatoren den Zugang zu den Dienstleistungen von Intravacc in den Bereichen Impfstoffentwicklung, analytische Entwicklung und...

Primrose Bio will supply its industry-leading carrier protein, PeliCRM197®, for vaccine developmentIntravacc has IP and know-how in vaccine conjugation and manufacturing of carrier protein based...

First in human phase I clinical study using OMV as an adjuvant for intranasal vaccinationAvacc 10® intranasal booster vaccine induces a mucosal response and no adverse eventsData will be presented at...

Intravacc secures $633K funding from CARB-X to develop a vaccine against or Neisseria gonorrhoeae.

Intravacc's new website offers an immersive user experience, showcasing their CDMO expertise vaccine platforms and a hub for scientific publications.

Intravacc and Sanquin Diagnostic Services optimized the in vitro Monocyte Activation Test (MAT) for OMV vaccinesMAT test potential replacement for the traditional rabbit pyrogen testing (RPT) for...

Mucosal route induces both localized and systemic immunityIntravacc is currently developing 3 OMV-based intranasal vaccinesArticle published in peer-reviewed journal ‘Current Opinions in Immunology’ ...